SMT202000255T1 - Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo - Google Patents

Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo

Info

Publication number
SMT202000255T1
SMT202000255T1 SM20200255T SMT202000255T SMT202000255T1 SM T202000255 T1 SMT202000255 T1 SM T202000255T1 SM 20200255 T SM20200255 T SM 20200255T SM T202000255 T SMT202000255 T SM T202000255T SM T202000255 T1 SMT202000255 T1 SM T202000255T1
Authority
SM
San Marino
Prior art keywords
neutralizing antibodies
neutralizing
antibodies
Prior art date
Application number
SM20200255T
Other languages
English (en)
Inventor
Mark Connors
Jinghe Huang
Byong Ha Kang
John Mascola
Elise Ishida
Tongqing Zhou
Peter Kwong
Anqi Zheng
Original Assignee
The United States Of America As Represented By The Secretary Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America As Represented By The Secretary Department Of Health And Human Services filed Critical The United States Of America As Represented By The Secretary Department Of Health And Human Services
Publication of SMT202000255T1 publication Critical patent/SMT202000255T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SM20200255T 2015-03-20 2016-03-18 Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo SMT202000255T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562136228P 2015-03-20 2015-03-20
US201562250378P 2015-11-03 2015-11-03
EP16716979.6A EP3271389B8 (en) 2015-03-20 2016-03-18 Neutralizing antibodies to gp120 and their use
PCT/US2016/023145 WO2016154003A1 (en) 2015-03-20 2016-03-18 Neutralizing antibodies to gp120 and their use

Publications (1)

Publication Number Publication Date
SMT202000255T1 true SMT202000255T1 (it) 2020-07-08

Family

ID=55755690

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200255T SMT202000255T1 (it) 2015-03-20 2016-03-18 Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo

Country Status (18)

Country Link
US (6) US10562960B2 (it)
EP (3) EP3271389B8 (it)
CN (1) CN108137676B (it)
AU (1) AU2016235541B2 (it)
CA (1) CA2980005A1 (it)
CY (1) CY1123068T1 (it)
DK (1) DK3271389T3 (it)
ES (1) ES2789348T3 (it)
HR (1) HRP20200583T1 (it)
HU (1) HUE049081T2 (it)
LT (1) LT3271389T (it)
PL (1) PL3271389T3 (it)
PT (1) PT3271389T (it)
RS (1) RS60270B1 (it)
SI (1) SI3271389T1 (it)
SM (1) SMT202000255T1 (it)
WO (1) WO2016154003A1 (it)
ZA (1) ZA201706155B (it)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000255T1 (it) 2015-03-20 2020-07-08 The United States Of America As Represented By The Secretary Department Of Health And Human Services Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo
KR102392142B1 (ko) 2016-10-21 2022-04-28 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
TWI728250B (zh) * 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
EP3641806A4 (en) 2017-06-22 2021-06-23 University of Maryland, Baltimore BROAD NEUTRALIZING ANTIBODIES AGAINST HIV
CN107098969B (zh) * 2017-06-28 2018-10-12 武汉波睿达生物科技有限公司 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
WO2019084018A1 (en) * 2017-10-23 2019-05-02 City Of Hope CAR FOR THE TREATMENT OF HIV INFECTION
CA3091437A1 (en) 2018-02-21 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2019173794A1 (en) * 2018-03-09 2019-09-12 Atreca, Inc. Anti-hiv antibodies
MX2020013621A (es) 2018-06-19 2021-03-25 Nantcell Inc Composiciones y metodos de tratamiento de vih.
HUE071524T2 (hu) 2018-07-03 2025-09-28 Gilead Sciences Inc HIV GP120-at célzó antitestek és alkalmazási eljárások
CN109251246B (zh) * 2018-09-14 2022-01-28 南开大学 Hiv-1广谱中和抗体及其用途
EP3870222A4 (en) * 2018-10-22 2022-07-27 International AIDS Vaccine Initiative ANTI-HIV ANTIBODIES
EP4464380A3 (en) 2018-12-04 2025-05-07 The Rockefeller University Hiv vaccine immunogens
IL286328B1 (en) 2019-03-22 2026-04-01 Gilead Sciences Inc Tricyclic bridging compounds of carbamoylpyridone and their pharmaceutical use
TWI762925B (zh) * 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
AU2020301161B2 (en) 2019-06-25 2023-10-26 Gilead Sciences, Inc. FLT3L-Fc fusion proteins and methods of use
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4445902A3 (en) 2019-12-24 2024-12-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US20230149319A1 (en) * 2020-04-13 2023-05-18 City Of Hope Cell-receptor targeted exosomes
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
JP7844430B2 (ja) * 2020-07-17 2026-04-13 ヤンセン バイオテツク，インコーポレーテツド 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体
ES3054072T3 (en) 2020-08-07 2026-01-29 Gilead Sciences Inc Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
AU2021333577B2 (en) 2020-08-25 2025-09-11 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
JP2024500322A (ja) * 2020-12-07 2024-01-09 ヴィーブ、ヘルスケア、カンパニー 併用療法
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
PT4440702T (pt) 2021-12-03 2025-08-13 Gilead Sciences Inc Compostos terapêuticos para a infecção pelo vírus do hiv
US20240425568A1 (en) * 2021-12-17 2024-12-26 Viiv Healthcare Company Combination therapies for hiv infections and uses thereof
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
EP4547659A1 (en) 2022-07-01 2025-05-07 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
KR20250036855A (ko) 2022-07-12 2025-03-14 길리애드 사이언시즈, 인코포레이티드 Hiv 면역원성 폴리펩타이드 및 백신, 및 이들의 용도
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
EP4676493A1 (en) * 2023-03-07 2026-01-14 Val-Chum, Limited Partnership Assays and reagents for the detection of soluble gp120
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
EP4719608A1 (en) 2023-05-31 2026-04-08 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
AU2024281548A1 (en) 2023-05-31 2025-11-13 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
EP4474392A1 (en) * 2023-06-09 2024-12-11 Universität zu Köln Broadly neutralizing antibodies targeting the cd4 binding site on hiv env
TW202504925A (zh) * 2023-06-09 2025-02-01 科隆大學 靶向ｈｉｖ ｅｎｖ上之ｃｄ４結合位點的廣譜性中和抗體
KR20260046169A (ko) 2023-07-28 2026-04-06 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
AU2024360779A1 (en) 2023-10-11 2026-04-16 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
CN122055369A (zh) 2023-10-11 2026-05-15 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2026076265A1 (en) 2024-10-03 2026-04-09 Gilead Sciences, Inc. Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP0630234B1 (en) 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2270461T3 (es) * 1996-06-03 2007-04-01 United Biomedical, Inc. Anticuerpos contra un complejo de cd4 y un dominio receptor de quemoquina, y sus usos contra las infecciones de vih.
US20030118985A1 (en) * 1997-05-14 2003-06-26 Hunt Jeffrey C. Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US7435549B1 (en) 1997-11-17 2008-10-14 Micromet Ag Method of identifying binding site domains that retain the capacity of binding to an epitope
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2264440T3 (es) 2000-03-24 2007-01-01 Micromet Ag Amplificacion de mrna.
WO2002016414A2 (en) 2000-08-22 2002-02-28 Micromet Ag Composition for the elimination of autoreactive b-cells
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003208839A1 (en) 2002-02-13 2003-09-04 Micromet Ag De-immunized (poly)peptide constructs
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
EP1629013B1 (en) 2003-05-31 2018-01-24 Amgen Research (Munich) GmbH Pharmaceutical composition comprising a bispecific antibody specific for epcam
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
ZA200601699B (en) 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
ME02191B (me) 2005-04-18 2016-02-20 Amgen Res Munich Gmbh Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
SI1976886T1 (sl) 2005-12-16 2015-03-31 Amgen Research (Munich) Gmbh Sredstva in postopki za zdravljenje tumorskih bolezni
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CN102576344A (zh) 2009-07-31 2012-07-11 惠普发展公司，有限责任合伙企业 识别和清点应用的方法和系统
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011046623A2 (en) 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies
ES2618380T3 (es) 2010-09-24 2017-06-21 International Aids Vaccine Initiative Novedosos anticuerpos con amplio poder neutralizante de VIH-1
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012154312A1 (en) * 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
CN116948019A (zh) 2011-05-17 2023-10-27 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
EP2736532B1 (en) 2011-07-25 2018-05-16 California Institute of Technology Compositions and methods for improving potency and breadth or hiv antibodies
IN2014CN02906A (it) 2011-10-20 2015-07-03 Us Health
AU2012347453B2 (en) 2011-12-08 2017-11-23 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
WO2013090644A2 (en) 2011-12-13 2013-06-20 California Institute Of Technology Anti-hiv antibodies having increased potency and breadth
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2828294A1 (en) 2012-03-23 2015-01-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
WO2014043386A1 (en) 2012-09-12 2014-03-20 Duke University Clonal lineage antibodies
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
SMT202000255T1 (it) 2015-03-20 2020-07-08 The United States Of America As Represented By The Secretary Department Of Health And Human Services Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo
CA3091437A1 (en) 2018-02-21 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use

Also Published As

Publication number Publication date
AU2016235541B2 (en) 2021-04-01
WO2016154003A1 (en) 2016-09-29
ES2789348T3 (es) 2020-10-26
PT3271389T (pt) 2020-05-13
EP3683233A1 (en) 2020-07-22
EP4620530A2 (en) 2025-09-24
CN108137676A (zh) 2018-06-08
CA2980005A1 (en) 2016-09-29
HUE049081T2 (hu) 2020-09-28
US12202886B2 (en) 2025-01-21
US20200231658A1 (en) 2020-07-23
EP4620530A3 (en) 2025-12-24
LT3271389T (lt) 2020-05-25
CN108137676B (zh) 2022-03-15
PL3271389T3 (pl) 2020-08-10
WO2016154003A8 (en) 2016-10-27
US20230060304A1 (en) 2023-03-02
RS60270B1 (sr) 2020-06-30
US12545719B2 (en) 2026-02-10
US20180298083A1 (en) 2018-10-18
US10562960B2 (en) 2020-02-18
AU2016235541A1 (en) 2017-09-28
ZA201706155B (en) 2022-05-25
EP3271389B8 (en) 2020-04-22
US20250179154A1 (en) 2025-06-05
CY1123068T1 (el) 2020-11-25
EP3271389B1 (en) 2020-02-12
HRP20200583T1 (hr) 2020-07-10
DK3271389T3 (da) 2020-04-27
US20210324053A1 (en) 2021-10-21
US20250215068A1 (en) 2025-07-03
SI3271389T1 (sl) 2020-09-30
EP3271389A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
ZA201706155B (en) Neutralizing antibodies to gp120 and their use
HUS2500022I1 (hu) Terápiás ellenanyagok és alkalmazásaik
IL267798B (en) Human antibodies to pd-1
IL266259A (en) Antibodies to pd-1 and uses thereof
ZA201803783B (en) Human immunodeficiency virus neutralizing antibodies
IL246661B (en) Human antibodies to pd–l1
PT3390451T (pt) Anticorpos humanos caninizados para il-4r alfa humano e canino
ES3066455T3 (en) Neutralizing anti-influenza b antibodies and uses thereof
GB201421430D0 (en) Antibodies to Adam17 and uses thereof
PL3233912T3 (pl) Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
EP3271022A4 (en) Hiv-1 neutralizing antibodies and uses thereof
PT3390441T (pt) Anticorpos neutralizantes do vírus da imunodeficiência humana
HK1242242A1 (en) Neutralizing anti-influenza b antibodies and uses thereof